Tryptamine Compounds for Mood Disorders With Reduced Psychoactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants are ineffective for a significant portion of patients with major depressive disorder, and tryptamines, despite their potential therapeutic benefits, are classified as Schedule I drugs with limited oral bioavailability and unsuitable for guided therapy due to their psychoactive effects and duration of action.
Innovation Solution
Development of tryptamine compounds, such as ethylpropyltryptamine (EPT) and methylethyltryptamine (MET), and their pharmaceutically acceptable salts, for treating mood disorders, including depressive, bipolar, anxiety, and other related disorders, with controlled administration to ensure safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidepressants are used, then treatment is provided, but effectiveness is poor for a significant portion of patients
Solution Approach 1:
The patent modifies the chemical structure of tryptamine compounds by changing parameters such as substituting hydrogen atoms at specific positions (e.g., 4-position of indole ring, 2-position of ethyl group) with different groups (fluoro, chloro, bromo, iodo, cyano, carboxyl, hydroxyl, amino, etc.). These parameter changes in molecular structure aim to optimize pharmacological properties and improve treatment effectiveness for depression while managing psychoactive effects.
2Reliability
If psychedelic tryptamines are used, then therapeutic effects are achieved, but psychoactive side effects and prolonged duration of action occur
Solution Approach 1:
The patent applies local quality modification by introducing specific substituents at specific positions of the tryptamine molecule. For example, placing electron-withdrawing groups at the 4-position of the indole ring or at the 2-position of the ethyl group creates localized chemical modifications that selectively alter receptor binding characteristics. This allows enhancement of therapeutic effects while suppressing unwanted psychoactive side effects through precise local structural changes.
Solution Approach 2:
The patent creates composite molecular structures by combining the core tryptamine scaffold with various functional groups and substituents. These composite compounds (e.g., fluorotryptamines, chlorotryptamines, cyanotryptamines, carboxyltryptamines) integrate multiple functional characteristics to achieve a balance between therapeutic benefits and reduced psychoactive effects.
3Duration of action of stationary object
If tryptamines with long duration of action are used, then therapeutic effect is sustained, but usability in guided therapy setting becomes challenging
Solution Approach 1:
The patent introduces dynamic control of duration of action by modifying the tryptamine structure with substituents that alter metabolic stability and receptor binding kinetics. Some compounds are designed with shorter durations suitable for guided therapy, while others have extended durations for maintenance treatment. This dynamic adjustment of temporal characteristics allows the same drug class to serve different therapeutic needs.
Data Source
AI summary
Methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds.